• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view.

作者信息

Cimadamore Alessia, Scarpelli Marina, Massari Francesco, Eckstein Markus, Gevaert Thomas, Cheng Liang, Lopez-Beltran Antonio, Montironi Rodolfo

机构信息

Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy.

Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.

出版信息

Expert Opin Biol Ther. 2020 Jun;20(6):539-544. doi: 10.1080/14712598.2020.1733965. Epub 2020 Feb 25.

DOI:10.1080/14712598.2020.1733965
PMID:32081061
Abstract
摘要

相似文献

1
Immunotherapy for urothelial cancer: from the diagnostic pathologist's point of view.尿路上皮癌的免疫治疗：从诊断病理学家的角度来看
Expert Opin Biol Ther. 2020 Jun;20(6):539-544. doi: 10.1080/14712598.2020.1733965. Epub 2020 Feb 25.
2
[PD-L1 : a natural immunosuppressor related to carcinogenesis. A pathologist's point of view].[程序性死亡受体配体1：一种与致癌作用相关的天然免疫抑制剂。病理学家的观点]
Rev Med Liege. 2021 May;76(5-6):392-397.
3
[Immunotherapy in urothelial carcinoma from a pathologist's perspective].[从病理学家角度看尿路上皮癌的免疫治疗]
Aktuelle Urol. 2017 Aug;48(4):336-339. doi: 10.1055/s-0043-110087. Epub 2017 Jun 14.
4
Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.头颈部鳞状细胞癌、尿路上皮癌和乳腺癌中程序性死亡配体 1 评分的观察者间和观察者内一致性。
Histopathology. 2020 Jan;76(2):191-200. doi: 10.1111/his.13946. Epub 2019 Sep 9.
5
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.膀胱尿路上皮癌及卡介苗诱导的肉芽肿中PD-L1（B7-H1）的表达：与局限性疾病进展的关联
Cancer. 2007 Apr 15;109(8):1499-505. doi: 10.1002/cncr.22588.
6
PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth".肺癌中的PD-L1检测：在未知的“中土世界”开展的一项国际病理学家倡议。
J Thorac Oncol. 2018 Sep;13(9):1239-1241. doi: 10.1016/j.jtho.2018.06.014.
7
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.膀胱癌中PD-1/PD-L1免疫检查点综述：从免疫逃逸介质到治疗靶点
Urol Oncol. 2017 Jan;35(1):14-20. doi: 10.1016/j.urolonc.2016.10.004. Epub 2016 Nov 3.
8
Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.膀胱癌免疫治疗的发展：靶向 PD(L)1 和 CTLA-4 通路的现状与未来。
World J Urol. 2018 Nov;36(11):1727-1740. doi: 10.1007/s00345-018-2332-5. Epub 2018 Jun 1.
9
[Tumors of the bladder. The pathologist's point of view].[膀胱肿瘤。病理学家的观点]
Ann Pathol. 1989;9(4):249-64.
10
Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.PD-L1 检测对帕博利珠单抗治疗美国晚期膀胱癌的成本效果和预算影响的影响。
Urol Oncol. 2019 Mar;37(3):180.e11-180.e18. doi: 10.1016/j.urolonc.2018.11.016. Epub 2018 Dec 6.

引用本文的文献

1
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems.病理学家的PD-L1图谱：适应证、评分、诊断平台及报告系统
J Pers Med. 2022 Jun 29;12(7):1073. doi: 10.3390/jpm12071073.
2
Programmed death ligand-1 (PD-L1) immunohistochemical assessment using the QR1 clone in muscle-invasive urothelial carcinomas: a comparison with reference clones 22C3 and SP263.程序性死亡配体-1（PD-L1）免疫组化评估使用 QR1 克隆在肌层浸润性尿路上皮癌：与参考克隆 22C3 和 SP263 的比较。
Virchows Arch. 2022 Feb;480(2):303-313. doi: 10.1007/s00428-021-03215-1. Epub 2021 Oct 20.
3
A narrative review of individualized treatments of genitourinary tumors: is the future brighter with molecular evaluations?
泌尿生殖系统肿瘤个体化治疗的叙述性综述：分子评估会让未来更光明吗？
Transl Androl Urol. 2021 Mar;10(3):1553-1561. doi: 10.21037/tau-20-1185.
4
Narrative review: update on immunotherapy and pathological features in patients with bladder cancer.叙述性综述：膀胱癌患者免疫治疗及病理特征的最新进展
Transl Androl Urol. 2021 Mar;10(3):1521-1529. doi: 10.21037/tau-20-1436.